RESEARCH TRIANGLE PARK, N.C.--()--Government payer reimbursement rates ranked as one of the most critical components to making portfolio management decisions, according to benchmarking research from Cutting Edge Information.
“The willingness of government payers to cover products is critical to large and small companies alike.”
As portfolio management teams work to maximize their companies’ revenue streams, they must determine which factors most impact their overall corporate goals. External market factors have a significant influence on the effectiveness of a company’s portfolio management strategies. While there are many considerations, some factors are more influential for future planning.
Cutting Edge Information’s study, “Pharmaceutical Portfolio Management: Selecting Targets, Filling Pipelines and Preparing for Post-Launch Success,” found that government payer reimbursement was considered more important than both internal research breakthroughs and private payer reimbursement rates in terms of their influence on portfolio management strategies. In fact, surveyed companies ranked government payer reimbursement rates second only to corporate finances.
“Many other portfolio planning decision drivers vary based on a company’s number of branded products and access to capital,” said Adam Bianchi, chief operating officer at Cutting Edge Information. “The willingness of government payers to cover products is critical to large and small companies alike.”
Today, government payers face pressure from the shaky economy and experience funding cuts in many developed countries. Combined with a wave of patent expirations that increased access to less expensive generics, pharmaceutical companies now face varied reimbursement challenges in these markets. New compounds must address an unmet need or substantially outperform available generics to gain favorable pricing.
“Pharmaceutical Portfolio Management: Selecting Targets, Filling Pipelines and Preparing for Post-Launch Success,” (http://www.cuttingedgeinfo.com/research/portfolio-management/strategy-resources/) explores portfolio management team structure, budgets and best practices, as well as lifecycle extension strategies. Use this report to:
- Bridge the gap between clinical portfolio management and brand lifecycle management
- Prioritize, support and protect assets throughout the entire product life
- Improve cross-functional communication to build strategy and drive coordinated execution
For more information about pharmaceutical portfolio management, contact Cassie Demeter at +1 919-403-6583.